Description: Sorrento Therapeutics, Inc., a development stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel and proprietary biotherapeutics for the treatment of cancer, inflammation, metabolic, and infectious diseases in the United States. The company's G-MAB, a human antibody library platform, facilitates the rapid identification and isolation of highly specific antibody therapeutic product candidates that bind to disease targets appropriate for antibody therapy. Its human antibody library technology is used to construct large human antibody libraries. It has license agreement with OPKO Health, Inc. to develop, manufacture, use, market, sell, offer to sell, import, and export certain products related to the development, manufacture, marketing, and sale of drugs for ophthalmological indications. Sorrento Therapeutics, Inc. is based in San Diego, California.
Home Page: www.sorrentotherapeutics.com
SRNE Technical Analysis
4955 Directors Place
San Diego,
CA
92121
United States
Phone:
858 203 4100
Officers
| Name | Title |
|---|---|
| Dr. Henry H. Ji Ph.D. | Chairman, Pres & CEO |
| Ms. Elizabeth Adkins Czerepak M.B.A. | Exec. VP, CFO & Chief Bus. Officer |
| Mr. Brian Cooley | Sr. VP of Corp. Communications & Lymphatic Drug Devel. BU |
| Mr. William J. Farley B.Sc. | VP of Sales & Bus. Devel. |
| Dr. Michael A. Royal J.D., M.D., MBA | SVP & Chief Medical Officer |
| Dr. Alexis Nahama D.V.M. | Sr. VP of Neurotherapeutics BU |
| Dr. Mark R. Brunswick | Sr. VP of Regulatory Affairs |
| Dr. Shawn Sahebi Ph.D. | Sr. VP of Commercial Operations |
| Dr. Robert D. Allen Ph.D. | Sr. VP of R&D |
| Dr. Xiao Xu M.D. | Pres of ACEA |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 1.1046 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 4.0084 |
| Price-to-Sales TTM: | 8.2922 |
| IPO Date: | 2010-01-11 |
| Fiscal Year End: | December |
| Full Time Employees: | 799 |